Clinical Trial

Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia

Study acronym: COMeBAC
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-05; most recent amendment 2026-04-24.
Trial Details
NCT Number NCT06726395
Lead Sponsor Region Skane
Conditions Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia), Staphylococcus (S.) Aureus Infection
Enrollment 420 participants
Start Date 2025-03-10
Primary Completion 2028-04 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-30